DalsnaFinance › Analyst accuracy › UBS › AMGN target
UBS lowers Amgen stock price target to $430 on drug trial concerns
UBS lowered its price target on Amgen Inc. (NASDAQ:AMGN) shares to $430 from $440
A fact about what UBS published, as reported by Investing.com, not a recommendation from Dalsna Finance; UBS is not affiliated with this site.
Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.